/
Immunology
Rheumatoid Arthritis
131
Pipeline Programs↗
183
Active Trials↗
150
Companies Involved↗
Rheumatoid Arthritis is a highly competitive landscape with 131 programs across 150 companies. The most active players are Eli Lilly, AstraZeneca, Roche. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical67
Phase 129
Phase 221
Phase 314
Approved
No programs
Analysis
Modality Breakdown
87%
Small molecule
97 of 112 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 112 classified programs, each share of the total. Modality classified for 95% of 131 pipeline programs.
Analysis
Trial Status
1,423
clinical trials
Completed981 · 69%
Terminated122 · 9%
Unknown status104 · 7%
Recruiting97 · 7%
Not yet recruiting47 · 3%
Active, not recruiting36 · 3%
Other36 · 3%
Clinical Trials
Trial Activity
1423 trials
A Dose-finding Phase I Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
Recruiting·—·Phase 1·NCT07245992·54 enrolled
Page 1 of 95
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)